# EDGAR Filing Document

**Accession Number:** 0001671584
**File Stem:** 0000950170-25-086571
**Filing Date:** 2025-6
**Character Count:** 2092
**Document Hash:** 862e80884304a35e58bfba9b000659f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-086571.hdr.sgml**: 20250718

**ACCESSION NUMBER**: 0000950170-25-086571

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aptevo Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001671584
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811567056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-838-0500

**MAIL ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

June 16, 2025

***VIA EDGAR***

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ms. Jessica Dickerson

**Re: Aptevo Therapeutics Inc.**

**Registration Statement on Form S-1<br>Filed June 16, 2025**

**File No. 333-288061**

Dear Ms. Jessica Dickerson:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-288061) of Aptevo Therapeutics Inc. (the "Registration Statement"). We respectfully request that the Registration Statement become effective as of 9:00 a.m., Eastern Time, on June 18, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.

Very truly yours,

Aptevo Therapeutics Inc.

By: <u>/s/ Marvin L. White</u>

Marvin L. White

President and Chief Executive Officer

CC: SoYoung Kwon, Aptevo Therapeutics Inc.<br>Daphne Taylor, Aptevo Therapeutics Inc. <br>Sean M. Donahue, Paul Hastings LLP

------